FDA rejects Chiasma's drug to treat growth disorder

21 Apr 2016


The U.S. Food and Drug Administration has rejected Chiasma Inc's experimental drug to treat adults with acromegaly, the company said on Friday.

Reuters


Related Topics

Adrenal Diabetes Metabolism Obesity Cardiovascular Bone Endocrine-Disrupting Chemicals Endocrine-Related Cancer Neuroendocrinology Reproduction Steroid and Steroidogenesis Thyroid

Share this story